Characterization of A-935142, a hERG enhancer, in the presence and absence of standard hERG blockers

Life Sciences

Volumn 90, Issue 15-16, 2012, Pages 607-611

  Liu, Xiaoqin ^a   Limberis, James T ^a   Su, Zhi ^a   Houseman, Kathryn ^a   Diaz, Gilbert J ^a   Gintant, Gary A ^a   Cox, Bryan F ^a   Martin, Ruth L ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

A 935142; Cardiac ion channel; Electrophysiology; hERG activator; Sotalol; Terfenadine

Indexed keywords

A 935142; DOFETILIDE; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL HERG; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; VOLTAGE CLAMP;

ACETIC ACIDS; ANALYSIS OF VARIANCE; ETHER-A-GO-GO POTASSIUM CHANNELS; HEK293 CELLS; HUMANS; PATCH-CLAMP TECHNIQUES; PHENETHYLAMINES; PYRAZOLES; SOTALOL; SULFONAMIDES; TERFENADINE; TRITIUM;

CAVIA;

EID: 84862800670     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2012.02.017     Document Type: Article

References (19)

1. O. Casis, S.P. Olesen, and M.C. Sanguineti Mechanism of action of a novel human ether-A-go-go-related gene channel activator Mol Pharmacol 69 2006 658 665 (Pubitemid 43121963)
2. o J Pharmacol Toxicol Methods 50 2004 187 199 (Pubitemid 39440716)
3. E. Gordon, I.M. Lozinskaya, Z. Lin, S.F. Semus, F.E. Blaney, and R.N. Willette 2-[2-(3,4-Dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels Mol Pharmacol 73 2008 639 651 (Pubitemid 351397869)
4. R.S. Hansen, T.G. Diness, T. Christ, J. Demnitz, U. Ravens, and S.-P. Olesen Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-Bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) Mol Pharmacol 69 2006 266 277 (Pubitemid 43048913)
5. R.S. Hansen, T.G. Diness, E. Wetter, U. Ravens, S.P. Olesen, and M. Grunnet Biophysical characterization of the new human ether-A-go-go-related gene channel opener NS3623 [N-(4-Bromo-2-(1H-tetrazol-5-yl)-phenyl)-N-(3-trifluoro- methylphenyl) urea Mol Pharmacol 70 2006 1319 1329 (Pubitemid 44435984)
6. R.S. Hansen, S.P. Oleson, and M. Grunnet Pharmacological activation of IKr current suppresses bradycardia-induced triggered activity in the isolated guinea pig heart J Pharmacol Exp Ther 321 2006 996 1002 (Pubitemid 46762682)
7. + channel Mol Pharmacol 67 2005 827 836 (Pubitemid 40365330)
8. + channels involved in variant 1 short QT syndrome J Mol Cell Cardiol 41 2006 563 566 (Pubitemid 44362993)
9. + channel mutation: differential impact on selected class I and class III antiarrhythmic drugs Br J Pharmacol 155 2008 957 966
10. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proc Natl Acad Sci U S A 97 2000 12329 12333
11. M. Mizobuchi, Y. Enjoji, R. Yamamoto, T. Ono, A. Funatsu, and D. Kambayashi Nifekalant and disopyramide in a patient with short QT syndrome: evaluation of pharmacological effects and electrophysiological properties Pacing Clin Electrophysiol 31 2008 1229 1232
12. + conductance Proc Natl Acad Sci U S A 106 2009 20075 20080
13. M. Perry, M. Sanguinetti, and J. Mitcheson Revealing the structural basis of action of hERG potassium channel activators and blockers J Physiol 588 2010 3157 3167
14. R. Schimpf, C. Veltmann, C. Giustetto, F. Gaita, M. Borggrefe, and C. Wolpert In vivo effects of mutant HERG K + channel inhibition by disopyramide in patrients with a short QT-1 syndrome: a pilot study J Cardiovasc Electrophysiol 18 2007 1157 1160 (Pubitemid 47609870)
15. Z. Su, J. Limberis, A. Souers, P. Kym, A. Mikhail, and K. Houseman Electrophysiologic characterization of a novel hERG channel activator Biochem Pharmacol 77 2009 1383 1390
16. X. Xu, M. Recanatini, M. Roberti, and G.-N. Tseng Probing the binding sites and mechanisms of action of two human ether-A-go-go-related gene channel activators, 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) and 2-[2-(3,4-dichloro-phyenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD307243) Mol Pharmacol 73 2008 1709 1721 (Pubitemid 351724359)
17. H. Zeng, I.M. Lozinskaya, Z. Lin, R.N. Willette, D.P. Brooks, and X. Xu Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator J Pharmacol Exp Ther 319 2006 957 962
18. Z. Zhou, G.B. Ye, Z. Fan, J.C. Makielski, G.A. Robertson, and C.T. January Properties of hERG channels stably expressed in HEK293 cells studied at physiological temperatures Biophys J 74 1998 230 241 (Pubitemid 28041752)
19. J. Zhou, C.E. Augelli-Szafran, J.A. Bradley, X. Chen, B.J. Koci, and W.A. Volberg Novel potent human ether-a-go-go-related gene (hERG) potassium channel enhancers and their in vitro antiarrhythmic activity Mol Pharmacol 68 2005 876 884 (Pubitemid 41206044)